Breast Cancer & Antiestrogenic Therapy & Brain

Summary

The study aims to investigate the effect of anti-estrogenic therapy in breast cancer patients on neural reward processing, psychosexual health, and quality of life, in reproductive vs. menopausal women. The investigators are directly comparing four groups 1) premenopausal women diagnosed with breast cancer receiving anti-estrogenic therapy, 2) postmenopausal women diagnosed with breast cancer with and without previous hormonal replacement therapy, receiving anti-estrogenic therapy, 3) premenopausal healthy women, and 4) postmenopausal healthy women. Furthermore, via assessment and integration of various data including subjective/self-report data via questionnaires and a standardized interview, physiological/endocrine (via blood sample), psychological and neural data (including anatomical scans, Diffusion tensor imaging (DTI), resting state, and a reward processing paradigm), this project will shed light on the connection between the brain, anti-estrogenic therapy, and psychosexual health.

Conditions

• Breast Cancer Female
• Healthy Female
• Menopause
• Anti-estrogenic Therapy

Interventions

DRUG

Tamoxifen

Tamoxifen is 20 mg once daily for two to three weeks.

DRUG

Letrozole

Letrozole (Aromatase inhibitor) is 2,5 mg once daily for two to three weeks.

DRUG

Letrozole + GnRH

When they take Letrozole + GnRh, the GnRh is an injection once a month.

Sponsors & Collaborators

• German Research Foundation

  collaborator OTHER

• University Hospital Tuebingen

  collaborator OTHER

• Uppsala University

  collaborator OTHER

• International Research Training Group 2804

  lead OTHER

Principal Investigators

• Birgit Derntl, Prof · Department of Psychiatry & Psychotherapy, University of Tuebingen

• Sara Brucker, Prof · Department of Women's Health University Women's Clinic

• Markus Hahn, Prof · Department of Women's Health University Women's Clinic

• Anna Wikman, Prof · Department of Women's and Children's Health, Reproductive Health

• Ann Christin Kimmig, Dr · Department of Psychiatry & Psychotherapy, University of Tuebingen

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

FEMALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-04-01

Primary Completion

2025-12-01

Completion

2026-04-01

Countries

• Germany

Study Locations